Incorporating Correlation in Interindividual Variability for the Optimal Design of Multiresponse Pharmacokinetic Experiments
暂无分享,去创建一个
Leon Aarons | Kayode Ogungbenro | Ivelina Gueorguieva | L. Aarons | K. Ogungbenro | Gordon Graham | I. Gueorguieva | G. Graham
[1] W. J. Studden,et al. Theory Of Optimal Experiments , 1972 .
[2] Gordon Graham,et al. A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models , 2007, Comput. Methods Programs Biomed..
[3] France Mentré,et al. Fisher information matrix for non‐linear mixed‐effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics , 2002, Statistics in medicine.
[4] Leon Aarons,et al. Optimum blood sampling time windows for parameter estimation in population pharmacokinetic experiments , 2006, Statistics in medicine.
[5] Lewis B. Sheiner,et al. Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects , 1992, Journal of Pharmacokinetics and Biopharmaceutics.
[6] France Mentré,et al. Optimization of Individual and Population Designs Using Splus , 2003, Journal of Pharmacokinetics and Pharmacodynamics.
[7] Malcolm Rowland,et al. Optimal Design for Multivariate Response Pharmacokinetic Models , 2006, Journal of Pharmacokinetics and Pharmacodynamics.
[8] Gordon Graham,et al. Optimal Design for Multiresponse Pharmacokinetic–Pharmacodynamic Models – Dealing with Unbalanced Designs , 2007, Journal of Pharmacokinetics and Pharmacodynamics.
[9] Brian Whiting,et al. Experimental design and efficient parameter estimation in population pharmacokinetics , 1990, Journal of Pharmacokinetics and Biopharmaceutics.
[10] Gordon Graham,et al. The use of a modified Fedorov exchange algorithm to optimise sampling times for population pharmacokinetic experiments , 2005, Comput. Methods Programs Biomed..
[11] J. Schellens,et al. Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule , 2002, Cancer Chemotherapy and Pharmacology.
[12] France Mentré,et al. Further Developments of the Fisher Information Matrix in Nonlinear Mixed Effects Models with Evaluation in Population Pharmacokinetics , 2003, Journal of biopharmaceutical statistics.
[13] Stephen B. Duffull,et al. The use of simulated annealing for finding optimal population designs , 2002, Comput. Methods Programs Biomed..
[14] Sergei Leonov,et al. OPTIMAL POPULATION DESIGNS FOR PK MODELS WITH SERIAL SAMPLING , 2004, Journal of biopharmaceutical statistics.
[15] Paolo Vicini,et al. Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments , 2005, The AAPS Journal.
[16] Alain Mallet,et al. Optimal design in random-effects regression models , 1997 .
[17] Stephen B. Duffull,et al. Optimal Design for Model Discrimination and Parameter Estimation for Itraconazole Population Pharmacokinetics in Cystic Fibrosis Patients , 2005, Journal of Pharmacokinetics and Pharmacodynamics.
[18] M. Foracchia,et al. POPED, a software for optimal experiment design in population kinetics , 2004, Comput. Methods Programs Biomed..
[19] France Mentré,et al. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs , 2001, Comput. Methods Programs Biomed..
[20] W. G. Hunter,et al. Design of experiments for parameter estimation in multiresponse situations , 1966 .